

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6686773

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	AMAG PHARMACEUTICALS, INC.	02/11/2021
RECEIVING PARTY DATA		
Name:	COVIS PHARMA GMBH	
Street Address:	GRAUFENAUWEG 12	
City:	6300 ZUG	
State/Country:	SWITZERLAND	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17245904
CORRESPONDENCE DATA		
Fax Number:	(703)836-7419	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	703-838-7596	
Email:	michele.shockey@bipc.com	
Correspondent Name:	BUCHANAN INGERSOLL & ROONEY PC	
Address Line 1:	1737 KING STREET, SUITE 500	
Address Line 4:	ALEXANDRIA, VIRGINIA 22314	
ATTORNEY DOCKET NUMBER:	0081864-000232	
NAME OF SUBMITTER:	MICHELE SHOCKEY	
SIGNATURE:	/Michele Shockey/	
DATE SIGNED:	04/30/2021	
Total Attachments: 2		
source=Assignment (company to company)#page1.tif		
source=Assignment (company to company)#page2.tif		

ASSIGNMENT

THIS ASSIGNMENT, having an effective date of November 16, 2020, by **AMAG PHARMACEUTICALS, INC.**, having a principal place of business at **1100 WINTER STREET, WALTHAM, MASSACHUSETTS 02451** (hereinafter referred to as "the Assignor"), respectively, witnesseth:

WHEREAS, the Assignor is the owner of the entire right, title and interest in and to the below-identified Letters Patent of the United States and applications for Letters Patent of the United States:

U.S. Patent Number	U.S. Patent Application Number	Title
6,599,498	09/521,264	Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohydrate derivatives
9,844,558	15/373,262	Methods of reducing risk of preterm birth
10,471,075	15/709,941	Methods of reducing risk of preterm birth
Not yet issued	16/580,669	Methods of reducing risk of preterm birth
10,556,922	15/764,100	Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
Not yet issued	16/301,237	Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same

AND WHEREAS, **COVIS PHARMA GmbH**, a limited liability company (*Gesellschaft mit beschränkter Haftung*) duly organized under and pursuant to the laws of **SWITZERLAND** and having a principal place of business at **GRAUFENAUWEG 12, 6300 ZUG, SWITZERLAND**, registered with the commercial register of the Canton of Zug under number CHE 403-495-189 (hereinafter referred to as "the Assignee"), is desirous of acquiring, and does hereby acquire, the entire right, title, and interest in and to said patents and patent applications.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the above-mentioned Letters Patent of the United States of America and applications for Letters Patent of the United States, and reissues and extensions of said Letters Patent, and all rights of priority associated therewith, the same to be held and enjoyed by the Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives, and assigns, to the full end of the term of said Letters Patent as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and

delivery of these presents, the Assignor is the lawful owner of the entire right, title, and interest in said Letters Patent and applications for Letters Patent, and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with any of said Letters Patent or application for Letters Patent, including interference and *inter partes* review proceedings, or any reissue or extension of any of said Letters Patent, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the maintenance, enforcement, and defense of said Letters Patent, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

AND the Assignor hereby requests the Commissioner of Patents to issue any said Letters Patent of the United States to the Assignee.

AMAG PHARMACUETICALS, INC.DATE: 2/11/2021By:  DocuSigned by:
DEA7C0098DA304D9...Name: Francesco TallaricoTitle: Secretary

Accepted by:

COVIS PHARMA GmbHDATE: 2/11/2021By:  DocuSigned by:
211495A6A10E4C5...Name: Fabio FazioTitle: SVP